Market capitalization | $14.19m |
Enterprise Value | $12.19m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 4.95 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-8.38m |
Free Cash Flow (TTM) Free Cash Flow | $-5.38m |
Cash position | $2.04m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
1 Analyst has issued a forecast Edesa Biotech Inc:
1 Analyst has issued a forecast Edesa Biotech Inc:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.19 -0.19 |
12%
12%
|
|
EBITDA | -8.19 -8.19 |
14%
14%
|
EBIT (Operating Income) EBIT | -8.38 -8.38 |
14%
14%
|
Net Profit | -6.93 -6.93 |
27%
27%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Edesa Biotech, Inc. is a biopharmaceutical company. It focuses on acquiring, developing and commercializing clinical stage drugs for dermatological and gastrointestinal indications with clear unmet medical needs. The company product candidate, EB01, is a sPLA2 inhibitor for the topical treatment of chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. Edesa Biotech was founded in 2007 and is headquartered in Markham, Canada.
Head office | Canada |
CEO | Pardeep Nijhawan |
Employees | 16 |
Founded | 2007 |
Website | www.edesabiotech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.